# A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

> **NCT03047395** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 2170 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** risankizumab

## Key facts

- **NCT ID:** NCT03047395
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-27
- **Primary completion:** 2023-11-29
- **Final completion:** 2023-11-29
- **Target enrollment:** 2170 (ACTUAL)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03047395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03047395, "A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03047395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*